Infectious Diseases
51
5
9
29
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.9%
3 terminated out of 51 trials
90.6%
+4.1% vs benchmark
20%
10 trials in Phase 3/4
17%
5 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (51)
Improved Child Nutrition and Development Through Social Transfers
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan
Prescription Support System for Antimicrobial Use in Belgian Primary Care
Fostering Prosocial Preventive Behaviours Through Awe
Rapamycin and Infection-related Illness
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Ascending Doses of BWC0977 in Healthy Volunteers
Real-world Multicentre Study of AZtreonam-AVIbactam Treatment With Infections or Suspected Infections Caused by Multidrug-resistant Gram-negative Bacteria
Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort
Omaha System-Based Health Application on Improving Knowledge, Attitude, and Behaviors Regarding Infectious Disease Prevention in the Community
Group B Strep Correlates of Protection Study
Biobank of Samples From Patients With Infectious Diseases
Key Technology Research and Application Demonstration of Individual Protective Equipment for High-Level Biosafety Laboratories
LoewenKIDS - Infections and the Development of the Immune System
The Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers
The Added Value of a Mobile Application of Community Case Management on Pediatric Referral Rates in Malawi
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers
Incidence of Allergic Manifestations and Infectious Episodes in Healthy Term Infants at Risk for Dysbiosis
Evaluate Bioequivalence of Burotam (1/1 g/Vial)